NCT04692103
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 2
Drug Category: Other
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes: Patients must be selected for an endocrine targeted therapy regimen for treatment of their breast cancer by the referring oncologist; Selected treatments may be part of experimental treatment protocols for which the patient would be separately consented
Exclusions:
https://ClinicalTrials.gov/show/NCT04692103